Petros Pharmaceuticals, Inc.
PTPINASDAQHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$171381
P/E Ratio—
52W High$0.04
52W Low$0.002
Petros Pharmaceuticals, Inc. (PTPI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PTPI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Gross Margin %(computed) | — | 76.28% | 71.98% | 61.79% | 79.52% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.02B | $0.02B | $0.02B | $0.02B |
| Operating Income | ($0.00B) | ($0.02B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Operating Margin %(computed) | — | -345.84% | -233.88% | -332.37% | -231.05% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.00B | ($0.01B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Net Margin %(computed) | — | -280.10% | -140.20% | -334.40% | -115.05% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.56 | $-3.34 | $-6.35 | $-9.68 | $-8.25 |
| Wtd Avg Shares | 0.28B | 0.01B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.00B) | ($0.01B) | ($0.00B) | ($0.01B) | ($0.00B) |
| EBITDA Margin %(computed) | — | -211.54% | -72.34% | -229.06% | -22.28% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Petros Pharmaceuticals, Inc. data
About Petros Pharmaceuticals, Inc. (PTPI) Income Statement
Petros Pharmaceuticals, Inc. (PTPI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PTPI reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of $0.00B — a net profit margin of —.
Frequently asked questions
PTPI · 4 questionsPetros Pharmaceuticals, Inc. (PTPI) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
PTPI revenuePTPI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09